Literature DB >> 12686305

Health care economic analyses and value-based medicine.

Melissa M Brown1, Gary C Brown, Sanjay Sharma, Jennifer Landy.   

Abstract

Health care economic analyses are becoming increasingly important in the evaluation of health care interventions, including many within ophthalmology. Encompassed with the realm of health care economic studies are cost-benefit analysis, cost-effectiveness analysis, cost-minimization analysis, and cost-utility analysis. Cost-utility analysis is the most sophisticated form of economic analysis and typically incorporates utility values. Utility values measure the preference for a health state and range from 0.0 (death) to 1.0 (perfect health). When the change in utility measures conferred by a health care intervention is multiplied by the duration of the benefit, the number of quality-adjusted life-years (QALYs) gained from the intervention is ascertained. This methodology incorporates both the improvement in quality of life and/or length of life, or the value, occurring as a result of the intervention. This improvement in value can then be amalgamated with discounted costs to yield expenditures per quality-adjusted life-year ($/QALY) gained. $/QALY gained is a measure that allows a comparison of the patient-perceived value of virtually all health care interventions for the dollars expended. A review of the literature on health care economic analyses, with particular emphasis on cost-utility analysis, is included in the present review. It is anticipated that cost-utility analysis will play a major role in health care within the coming decade.

Entities:  

Mesh:

Year:  2003        PMID: 12686305     DOI: 10.1016/s0039-6257(02)00457-5

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  43 in total

1.  Value based medicine.

Authors:  M M Brown; G C Brown
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

Review 2.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 3.  Value-based medicine and ophthalmology: an appraisal of cost-utility analyses.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Heidi Brown; Lindsay Smithen; David B Leeser; George Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2004

4.  Value based medicine.

Authors:  S M Kymes; K D Frick
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

5.  Utility analysis tells all.

Authors:  M Brown
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 6.  [Value-based medicine in ophthalmology].

Authors:  C Hirneiss; A S Neubauer; C Tribus; A Kampik
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 7.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

8.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  [Visual quality of life after vitreoretinal surgery for epiretinal membranes].

Authors:  C Hirneiss; F Rombold; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2006-02       Impact factor: 1.059

10.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.